SIGHT SCIENCES INC (SGHT)
Health Care · Ophthalmology medical devices · NASDAQ
Sight Sciences develops minimally invasive interventional devices for glaucoma and dry eye, targeting ophthalmology markets through reimbursement-focused commercialization.
What SIGHT SCIENCES INC does
Sight Sciences is an ophthalmology medical device company that develops and commercializes minimally invasive interventional solutions for eye diseases. The company focuses on two primary product areas: Interventional Glaucoma treatments and Interventional Dry Eye solutions. Sight Sciences designs devices aimed at treating these conditions through novel procedural approaches, with a business model centered on obtaining and maintaining reimbursement while scaling sales to existing and new customers.
Themes: ophthalmology / eye care, glaucoma treatment, dry eye treatment, minimally invasive medical devices, interventional procedures
Fundamentals
- Price$8.26 as of 2026-08-21 close
- Market cap$455M as of 2026-08-21
- 1-year return+100.5% 2025-08-21 close $4.12 → 2026-08-21 close $8.26
- P/En/a negative earnings
- Net margin-35.7% as of 2026-08-24
- Gross margin+88.4% as of 2026-08-24
- ROE-50.6% as of 2026-08-24
- Debt / equity0.77 as of 2026-08-24
- Revenue growth (YoY)+9.3% as of 2026-08-24
- Revenue CAGR (3y)+2.7% SEC XBRL
- Beta2.49 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How SGHT compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SIGHT SCIENCES INC looks technically
SIGHT SCIENCES INC (SGHT) is trading 43.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 75, in overbought territory (above 70). It made a new 20-day high about 3 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 43.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +43.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.92 | $5.92 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.77 | $5.77 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 4.41. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal | 3 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 43.2% above | +43.2% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 36.7 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 75, in overbought territory (above 70) | 74.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($5.25 to $8.85) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 83.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.24 | $9.24 |
|---|---|---|
| From the 52-week high | it is 10.6% below its 52-week high (its highest price of the past year) | -10.6% |
| Above the 52-week low | it is 158.9% above its 52-week low (its lowest price of the past year) | +158.9% |
| Below the 52-week high | it is 10.6% below its highest point of the past year | 10.6% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $42.57 (set on 2021-08-02) | $42.57 |
| Given back of the 52-week move | over the past year its closes ranged ($3.20 to $9.05), and it has given back only a small part of its rise from last year’s low — 14% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.25 to $5.43. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 13.5% |
| From the all-time high | it is 80.6% below its all-time high | -80.6% |
| Nearest price level | it is trading 2.8% above a support level at $8.03 — a price it turned at twice since 2025-11-12, most recently on 2025-12-16. Since 2024-08-21 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.8% |
| All-time low | its lowest closing price on record is $1.04 (set on 2023-10-27) | $1.04 |
| Above the all-time low | it is 694.2% above its all-time low | +694.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4613 between its high and its low — about 5.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4613 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.29 and $9.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.29 – $6.95 – $9.61 |
| Typical daily range (% of price) | its price moves about 5.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.6% |
| Stretch from the 200-day average | it is trading 5.4 daily ranges above its 200-day average price (43.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.69× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 4.7% since the prior reading | +4.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Open gap | it gapped 4.3% above the previous close 11 sessions ago and has not traded back through the level it left behind at 5.55 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.3% |
| Gap filled | a 2.7% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 65.9 percentage points (the stock gained 68.2% while the market gained 2.3%) | +65.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 57.6 percentage points (the stock gained 60.7% while the market gained 3.1%) | +57.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 41.9 percentage points (the stock gained 53.0% while the market gained 11.1%) | +41.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 80.0 percentage points (the stock gained 100.5% while the market gained 20.5%) | +80.0% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 58% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.4% of the share price. | +57.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 56% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.30 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +55.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $7.71 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +7.2% |
Price levels it has turned at before
SGHT last closed at $8.26 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.03 | Support | 2.8% below the last close | turned there twice · 2025-11-12 to 2025-12-16 |
| $8.78 | Resistance | 6.2% above the last close | turned there twice · 2025-11-28 to 2025-12-08 |
| $6.58 | Support | 20.4% below the last close | turned there twice · 2025-11-21 to 2026-02-03 |
| $5.92 | Support | 28.4% below the last close | turned there twice · 2026-01-26 to 2026-06-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $4.41.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $6.08 and $7.12 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $4.41.
This labelling was already in place when we began recording count changes on 2026-08-12, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.71 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$9.00 range $8.00 – $12.00; median $8.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SGHT
- Consensus EPS estimate-$0.1273 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reimbursement risk: ability to obtain and maintain sufficient reimbursement for Interventional Glaucoma products and establish broad reimbursement for Interventional Dry Eye products","Regulatory and competitive risk: need to compete effectively with existing competitors and new market entrants in a highly competitive and rapidly changing environment","Capital and financing risk: need for additional financing and ability to maintain compliance with secured credit facility terms"]
What changed in the latest 10-Q
AI-assisted comparison of SGHT's 10-Q filed 2026-05-06 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for 'Management's Discussion and Analysis of Financial Condition and Results of Operations' changed from 24 (filed 2025-11-06) to 22 (filed 2026-05-06)
- Page number for 'Quantitative and Qualitative Disclosures About Market Risk' changed from 35 (filed 2025-11-06) to 29 (filed 2026-05-06)
- Page number for 'Controls and Procedures' changed from 36 (filed 2025-11-06) to 30 (filed 2026-05-06)
- Page number for 'PART II. OTHER INFORMATION' changed from 36 (filed 2025-11-06) to 30 (filed 2026-05-06)
- Page number for 'Legal Proceedings' changed from 36 (filed 2025-11-06) to 30 (filed 2026-05-06)
- Notes:
- Only the table of contents page numbers are provided in both filings; the actual MD&A content cannot be compared from the source text supplied
Risk Factors
- Added:
- Added bullet point in newer filing (2026-05-06): 'our ability to enter into and compete in new markets'
- Added language in newer filing (2026-05-06): 'our abilities to protect and scale our intellectual property portfolio and to prosecute intellectual property litigation to a successful conclusion'
- Added reference in newer filing (2026-05-06) to Annual Report for year ended December 31, 2025 filed on March 4, 2026
- Added in newer filing (2026-05-06): 'Short-term debt, net' line item of $3,797 thousand in current liabilities
- Removed:
- Removed from newer filing (2026-05-06): reference to 'our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 filed with the SEC on May 8, 2025 and August 7, 2025, respectively' (present in older filing filed 2025-11-06)
- Removed from newer filing (2026-05-06): reference to Annual Report for year ended December 31, 2024 filed on March 7, 2025 (present in older filing filed 2025-11-06)
- Reworded:
- Changed in newer filing (2026-05-06) from 'Surgical Glaucoma products and expand and maintain sufficient reimbursement for our Dry Eye products' to 'Interventional Glaucoma products and establish broad reimbursement for our Interventional Dry Eye products'
- Changed in newer filing (2026-05-06) from 'our ability to protect and scale our intellectual property portfolio' to 'our abilities to protect and scale our intellectual property portfolio and to prosecute intellectual property litigation to a successful conclusion'
- Quarterly period changed from 'September 30, 2025' in older filing to 'March 31, 2026' in newer filing
- Balance sheet comparison dates changed from 'September 30, 2025 and December 31, 2024' in older filing to 'March 31, 2026 and December 31, 2025' in newer filing
- Notes:
- The provided text sections appear to be table of contents and forward-looking statements sections, not the full Risk Factors section
- Financial data (balance sheet) is included in the excerpts but is not part of the Risk Factors section being compared
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 6 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($68794) · 6 sells ($448413) — 1 buying, 6 selling insiders
- Last 180 days1 buy ($68794) · 13 sells ($825386) — 1 buying, 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SGHT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SGHT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,103,949
- Reported value $15,471,890
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SGHT had 826,710 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SGHT had 1.50% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.53 days to cover at the same settlement.
- Reported short interest (shares) 826,710
- Short interest (% of shares outstanding) 1.50%
- Prior settlement (shares) 829,847
- Reported change -0.38%
- Days to cover (reported) 5.53
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alcon
- Bausch + Lomb
- Johnson & Johnson Vision
- Glaukos
- Ivantis
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SGHT vs…
Frequently asked questions
What does SIGHT SCIENCES INC (SGHT) do?
Sight Sciences is an ophthalmology medical device company that develops and commercializes minimally invasive interventional solutions for eye diseases. The company focuses on two primary product areas: Interventional Glaucoma treatments and Interventional Dry Eye solutions. Sight Sciences designs devices aimed at treating these conditions through novel procedural approaches, with a business model centered on obtaining and maintaining reimbursement while scaling sales to existing and new…
What sector is SIGHT SCIENCES INC (SGHT) in?
SIGHT SCIENCES INC (SGHT) is classified in the Health Care sector. Its industry is Ophthalmology medical devices. It trades on NASDAQ.
Who are SIGHT SCIENCES INC's (SGHT) competitors?
Notable peers of SIGHT SCIENCES INC (SGHT) include Alcon, Bausch + Lomb, Johnson & Johnson Vision, Glaukos and Ivantis. This peer set is informational only — not financial advice.
Is SIGHT SCIENCES INC (SGHT) overbought or oversold right now?
SIGHT SCIENCES INC (SGHT) is currently in overbought territory (its 14-day RSI is 75, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SGHT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.